Composition BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of BPC-157 and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of two co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation Lot-specific COA Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
The peptide interacts with the nitric oxide (NO) system, modulating vascular tone and cell signaling at the microenvironmental level to support the transition from the inflammatory phase to the proliferative phase of healing
Full-length thymosin beta-4 is a 43-residue protein-like peptide and is not chemically identical to the seven-residue TB-500 fragment
Individual results vary based on each patients health history, laboratory findings, and clinical presentation
pH matters more
EGRIFTA WR stimulates GH production and increases serum IGF-1, a growth factor
